Clinical trial
A Phase 1/2 Dose-exploration and Dose-expansion Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease
NCT06389877 is registered in ClinicalTrials.gov with Beam Therapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Dose-exploration and Dose-expansion Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease
- Lead sponsor
- Beam Therapeutics Inc.
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- June 19, 2024
- Completion date
- May 31, 2030
- Enrollment
- 192 (estimated)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.